©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2015; 7(12): 375-382
Published online Dec 15, 2015. doi: 10.4251/wjgo.v7.i12.375
Published online Dec 15, 2015. doi: 10.4251/wjgo.v7.i12.375
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
Cosimo Sperti, Lucia Moletta, Stefano Merigliano, Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua, 35128 Padua, Italy
Author contributions: Sperti C and Moletta L conceived the article and drafted the manuscript; Merigliano S made critical review; all authors read and approved the final manuscript.
Conflict-of-interest statement: None to declare.
Correspondence to: Cosimo Sperti, MD, Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua, via Giustiniani 2, 35128 Padova, Italy. csperti@libero.it
Telephone: +39-049-8218845 Fax: +39-049-8218821
Received: May 27, 2015
Peer-review started: May 30, 2015
First decision: August 25, 2015
Revised: September 9, 2015
Accepted: October 23, 2015
Article in press: October 27, 2015
Published online: December 15, 2015
Processing time: 200 Days and 23.7 Hours
Peer-review started: May 30, 2015
First decision: August 25, 2015
Revised: September 9, 2015
Accepted: October 23, 2015
Article in press: October 27, 2015
Published online: December 15, 2015
Processing time: 200 Days and 23.7 Hours
Core Tip
Core tip: Different therapeutic options are available for the treatment of patients with pancreatic adenocarcinoma recurrence, even if only few data have been reported in the Literature on their effective benefit for patients’ outcome. In this work we present the current English Literature about this issue, the possible indications for the different therapeutic options and the available data on patients’ outcome.